Development and longevity of antibodies against SARS-CoV-2 in kidney transplant recipients after symptomatic COVID-19
Transpl Infect Dis
.
2021 Aug;23(4):e13646.
doi: 10.1111/tid.13646.
Epub 2021 Jun 1.
Authors
Divya Bajpai
1
,
Deepal Shah
2
,
Sreyashi Bose
1
,
Satarupa Deb
1
,
Chintan Gandhi
1
,
Tulsi Modi
1
,
Nikhil Rao
1
,
Kruteesh Kumar
1
,
Nikhil Saxena
1
,
Abhinav Katyal
1
,
Ankita Patil
1
,
Sayali Thakare
1
,
Atim E Pajai
1
,
Gita Nataraj
2
,
Tukaram E Jamale
1
Affiliations
1
Department of Nephrology, Seth G.S.M.C. and K.E.M. Hospital, Mumbai, India.
2
Department of Microbiology, Seth G.S.M.C. and K.E.M. Hospital, Mumbai, India.
PMID:
34028939
PMCID:
PMC8209871
DOI:
10.1111/tid.13646
No abstract available
Keywords:
COVID-19; anti-SARS-CoV-2 antibodies; immunological response; kidney transplantation.
Publication types
Letter
Comment
MeSH terms
Antibodies
COVID-19*
Humans
Kidney Transplantation* / adverse effects
SARS-CoV-2
Transplant Recipients
Substances
Antibodies